Skip to main content
. Author manuscript; available in PMC: 2013 Jun 13.
Published in final edited form as: Drug Metabol Drug Interact. 2013;28(1):59–63. doi: 10.1515/dmdi-2012-0031

Table 1.

Study population characteristics grouped by CYP3A4/5 combined genotype.

Poor
metabolizers
Intermediate
metabolizers
Extensive
metabolizers
Number 19 (8%) 167 (71%) 49(21%)
Atorvastatin dose (n=142) 20 (10,20) 20(10,40) 20 (20,40)
Simvastatin dose (n=84) 20 (10,40) 40 (20,40) 40 (20,40)
Lovastatin dose (n=9) 20 (20,20) 20(20,40) −(−,−)
Combined dose (n=235)a 16.6 (10,20) 23.2(16.6,40) 33.2(16.6,40)
Age
 Combined (all three statins) 64±12 63±11 5 6±9
Male
 Combined (all three statins) 13(8%) 113 (72%) 32 (20%)
Caucasian
 Combined (all three statins) 19 (9%) 160 (77%) 29 (14%)

Data for age are mean±SD. Data for number, race, and gender represent number and percentage. Data for dose represent the median (first quartile, third quartile) for each metabolizer group and statin type.

a

Combined statin dose was calculated by first determining an atorvastatin-equivalent dose for simvastatin and lovastatin (i.e., simvastatin and lovastatin have 83% and 58% the potency, respectively, of atorvastatin [5]).